Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
40.37 USD -1.66% Intraday chart for Apellis Pharmaceuticals, Inc. +2.85% -32.56%
May. 31 Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target MT
May. 24 Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Mixed Premarket Friday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLS Stock
  4. News Apellis Pharmaceuticals, Inc.
  5. Other languages